Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.
Laronde has raised $440.0M in total funding. The most recent round was Series B. The last funding was announced in August 2021.
Laronde's investors include BlackRock, Fidelity, Flagship Pioneering, Invus, CPP Investments.
Laronde is headquartered in Cambridge, United States.
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.
Laronde is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Laronde — Funding & Investors." VCBacked, August 30, 2021, https://www.vcbacked.co/company/laronde. Accessed September 30, 2026.
VCBacked. (2021). Laronde — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/laronde
{{cite web |title=Laronde — Funding & Investors |url=https://www.vcbacked.co/company/laronde |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated